Novastan® (brand of argatroban): A small-molecule, direct thrombin inhibitor

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 6, 1997, Pages 503-516

  Hursting, Marcie J ^a   Alford, Kenneth L ^a   Becker, Jean Claude P ^a   Brooks, R Lynn ^a   Joffrion, James L ^a   Knappenberger, Gary D ^a   Kogan, Patricia W ^a   Kogan, Timothy P ^a   Mckinney, Anthony A ^a   Schwarz Jr, Richard P ^a  

^a TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

Anticoagulation; Antithrombotic agents; Argatroban; Pharmacology; Thrombin inhibitors; Thrombolysis

Indexed keywords

ABCIXIMAB; ARGATROBAN; HEPARIN; HIRUDIN; THROMBIN INHIBITOR; ANTITHROMBIN; PIPECOLIC ACID DERIVATIVE;

ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONFERENCE PAPER; DOSE KIDNEY FUNCTION RELATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FIBRINOLYSIS; HEADACHE; HEMOSTASIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; VERTIGO; ANIMAL; CHEMICAL STRUCTURE; DRUG SCREENING; FIBRINOLYTIC THERAPY; HEART INFARCTION; MOLECULAR WEIGHT; REVIEW;

ANIMALS; ANTITHROMBINS; CLINICAL TRIALS, PHASE I; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; MYOCARDIAL INFARCTION; PIPECOLIC ACIDS; THROMBOLYTIC THERAPY;

EID: 15144361588     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996128     Document Type: Conference Paper

References (61)

1. Fenton JW, FA Ofosu, DG Moon, JM Maraganore: Thrombin structure and function: why thrombin is the primary target for antithrombotics. Blood Coag Fibrinolys 2:64-75, 1991.
2. Hirsh J: Heparin. N Engl J Med 324:1565-1574, 1991.
3. Hirsh J, MN Levine: Low molecular weight heparin. Blood 79: 1-17, 1992.
4. Hirsh J: Oral anticoagulant drugs. N Engl J Med 324:1865-1875, 1991.
5. Callas D, J Fareed: Comparative pharmacology of site directed antithrombin agents. Implications in drug development. Thromb Haemostas 74:473-481, 1995.
6. 2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)-sulfonyl-]L-arginyl)-2- piperidinecarboxylic acid. Biochemistry 23:85-90, 1984.
7. Bush LR: Argratroban: A selective potent thrombin inhibitor. Cardiovasc Drug Rev 9:247-263, 1991.
8. Matsuo T, K Kario, S Matsuda, N Yamaguchi, E Kakishita: Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: A multicenter clinical trial of argatroban. J Thromb Thrombolysis 2:131-136, 1995.
9. Rawson TE, KA VanGorp, J Yang, TP Kogan: Separation of 21-(R)- and 21-(S)-argatroban: Solubility and activity of the individual diastereoisomers. J Pharm Sci 82:672-673, 1993.
10. Markwardt F: Development of hirudin as an antithrombotic agent. Semin Thromb Hemost 15:269-282, 1989.
11. Hijikata-Okunomiya A, S Okamoto: A strategy for a rational approach to designing synthetic selective inhibitors. Semin Thromb Hemost 18:135-149, 1992.
12. Okamoto S, A Hijikata: Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereostructure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 101:440-446, 1981.
13. Braun PJ, S Dennis, J Hofsteenge, SR Stone: Site-directed mutagenesis to investigate the basis for the specificity of hirudin. Biochemistry 27:6517-6522, 1988.
14. Jackson CM: Mechanisms of prothromhin activation. In: Colman RW, J Hirsh, VJ Marder, EW Salzman (eds): Hemostasis and Thrombosis. 2nd ed. Lippincott, Philadelphia, 1987, pp 1373-1382.
15. Naski MC, JA Shafer: A kinetic model for the α-thrombin-catalyzed conversion of plasma levels of fibrinogen in the presence of antithrombin III. J Biol Chem 266:13003-13010, 1991.
16. Lawson JH, M Kalafatis, S Stram, KG Mann: A model for the tissue factor pathway to thrombin. J Biol Chem 269:23367-23373, 1994.
17. Berry CN, C Girardot, C Lecoffre, C Lunven: Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin. Thromb Haemostas 72:381-386, 1994.
18. Gast A, T Tschopp, G Schmid, K Hilpert, J Ackermann: Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coag Fibrinolysis 5:879-887, 1994.
19. Weitz JI, M Hudoda, D Masel, J Maraganore, J Hirsh: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 86:385-391, 1990.
20. Green D, C Ts'ao, N Reynolds, D Kahn, H Kohl, I Cohen: In vitro studies of a new synthetic thrombin inhibitor. Thromb Res 37:145-153, 1985.
21. Tamao Y, T Yamamoto, R Kikumoto, H Hara, J Itoh, T Hirata, et al: Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo. Thromb Haemostas 56:28-34, 1986.
22. Berry CN, D Girard, S Lochot, C Lecoffre: Antithrombotic actions of argatroban in rat models of venous, "mixed" and arterial thrombosis, and its effects on the tail transaction bleeding time. Br J Pharmacol 113:1209-1214, 1994.
23. Winn MJ, K Jain, DD Ku: Argatroban and inhibition of the vasomotor actions of thrombin. J Cardiovasc Pharmacol 22:754-760, 1993.
24. Nishiyama H, K Umemura, AR Saniabadi, Y Takiguchi, T Uematsu, M Nakashima: Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model. Eur J Pharmacol 264:191-195, 1994.
25. Jang I-K, HK Gold, RC Leinbach, TJ Fallon, D Collen: In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res 67:1552-1561, 1990.
26. Mellott MJ, TM Connelly, SJ York, LR Bush: Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis. Thromb Haemostas 64:526-534, 1990.
27. 2 modulate the response to tissue type plasminogen activator in vivo. Circ Res 65:83-94, 1989.
28. 2 in reocclusion following coronary thrombolysis with tissue plasminogen activator. Proc Natl Acad Sci USA 86: 7585-7589, 1989.
29. Yasuda T, HK Gold, H Yaoita, RC Leinbach, JL Guerrero, I-K Jang, et al: Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue type plasminogen activator in a canine preparation. J Am Coll Cardiol 16:714-722, 1990.
30. Callas DD, D Hoppensteadt, J Fareed: Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Semin Thromb Hemost 21:177-183, 1995.
31. Kaiser B, J Fareed, D Hoppensteadt, B Birdsong, JM Walenga, F Markwardt: Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systems. Thromb Res 65:157-164, 1992.
32. Kaiser B, D Callas, D Hoppensteadt, K Mallinowska, J Fareed: Comparative studies on the inhibitory spectrum of recombinant hirudin, DuP 714 and heparin on the generation of thrombin and factor Xa generation in biochemically defined systems. Thromb Res 73:327-335, 1994.
33. Iida S, T Komatsu, T Hirano, Y Fujimura, H Nakai, K Kitazawa, et al: Pharmacokinetic studies of argipidine (MD-805) in dogs and rabbits. Blood or plasma level profile, metabolism, excretion and accumulation after single or consecutive intravenous administration of argipidine. Oyo Yakuri 32:1117-1127, 1986.
34. Antman EM, for the TIMI 9A Investigators: Hirudin in acute myocardial infarction: Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 90:1624-1630, 1994.
35. GUSTO IIA Investigators: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90:1631-1637, 1994.
36. Izawa O, M Katsuki, T Komatsu, S Iida: Pharmacokinetics studies of argatroban (MD-805) in human concentrations of argatroban and its metabolites in plasma, urine and feces during and after drip intravenous infusion. Jpn Pharmacol Ther 14: 251-263, 1986.
37. Greinacher A: Antigen generation in heparin-associated thrombocytopenia: The nonimmunologic type and the immunologic type are closely linked in their pathogenesis. Semin Thromb Hemost 21:106-116, 1995.
38. Kelton JG, TE Warkentin: Heparin-induced thrombocytopenia: What the serologists have taught us. J Lab Clin Med 128:346-348, 1996.
39. Magnani HN: Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemostas 70:554-561, 1993.
40. Warkentin TE, CPM Haywood, LK Boshkov, AV Santos, JA Sheppard, AP Bode, JG Kelton: Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84:3691-3699, 1994.
41. Sheridan D, C Carter, JG Kelton: A diagnostic test for heparin-induced thrombocytopenia. Blood 67:27-30, 1986.
42. 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 104:648-654, 1995.
43. Warkentin TE, MN Levine, J Hirsh, P Horsewood, RS Roberts, M Gent, JG Kelton: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330-1335, 1995.
44. Lewis BE, FS Leya, D Wallis: Failure of ancrod in the treatment of heparin-induced arterial thrombosis. Can J Cardiol 10:559-565, 1994.
45. Lewis BE, R Iaffaldano, TL McKiernan, L Rao, J Donkin, JM Walenga: Report of successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Cathet Cardiovasc Diagn 38:206-209, 1996.
46. Topol EJ: Thrombolytic intervention. In: Topol EJ (ed): A Textbook of Interventional Cardiology. Saunders, Philadelphia, 1994, pp 68-111.
47. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673-682, 1993.
48. The GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329:1615-1622, 1993.
49. Becker RC: Improving the efficacy and stability of coronary reperfusion following thrombolysis: Exploring the thrombin hypothesis. J Thromb Thrombolysis 1:133-144, 1995.
50. Cannon CP, CH McCabe, TD Henry: A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 5 trial. J Am Coll Cardiol 23:993-1003, 1994.
51. Lee LV, for the TIMI 6 Investigators: Initial experience with hirudin and streptokinase in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 6 trial. Am J Cardiol 75:7-13, 1995.
52. Antman EM, for the TIMI 9A Investigators: Hirudin in acute myocardial infarction: Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 90:1624-1632, 1994.
53. GUSTO IIa Investigators: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90:1631-1637, 1994.
54. Neuhaus K-L, R Essen, U Tebbe, A Vogt, M Roth, M Riess, et al: Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study: A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 90:1638-1642, 1994.
55. Sobel BE: Intracranial bleeding, fibrinolysis, and anticoagulation: Causal connections and clinical implications. Circulation 90:2147-2152, 1994.
56. Théroux P, F Pérez,-Villa, D Waters, J Lespérance, F Shabani, R Bonan: Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 91:2132-2139, 1995.
57. Gold HK, FW Torres, HD Garabedian, W Werner, I-K Jang, A Khan, et al: Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 21:1039-1047, 1993.
58. Théroux P, D Waters, J Lam, M Juneau, J McCans: Reactivation of unstable angina following discontinuation of heparin. N Engl J Med 327:141-145, 1992.
59. Willerson JT, W Casscells: Thrombin inhibitors in unstable angina: rebound or continuation of angina after argatroban withdrawal? J Am Coll Cardiol 21:1048-1051, 1993.
60. Zoldhelyi P, J Bichler, WG Owen, DE Grill, V Fuster, JS Mruk, JH Chesebro: Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 90: 2671-2678, 1994.
61. Becker RC, EG Bovill, JM Corrao: Dynamic nature of thrombin generation, fibrin formation, and platelet activation in unstable angina and non-Q-wave myocardial infarction. J Thromb Thrombolys 2:57-64, 1995.